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ABSTRACT
Type 2 diabetes (T2D) is a progressive disease
affecting glucose regulation and a major cause of
morbidity and mortality globally. Many patients
are not escalated up the treatment ladder
appropriately despite failing to achieve glycemic
control, with barriers such as fear of hypoglycemia, weight gain, and treatment burden
recognized as factors. Exogenous basal insulin is
titrated to address control of fasting plasma glucose and may preserve residual b-cell function,
thus promoting a greater endogenous prandial
insulin response. Native glucagon-like peptide-1
(GLP-1) is a peptide hormone secreted by the gut
in response to nutrient ingestion; it increases
insulin secretion, inhibits glucagon secretion,
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and prolongs gastric emptying, thereby lowering
overall food intake. As its glucose-lowering
action is glucose dependent, a GLP-1 receptor
agonist (GLP-1RA) achieves these benefits with a
lower risk of hypoglycemia compared with other
diabetes therapies. Two products, an insulin
degludec/liraglutide combination (IDegLira) and
an insulin glargine/lixisenatide combination
(IGlarLixi), were approved for use in adults with
T2D by the US Food and Drug Administration in
2016. The efficacy and safety of these two basal
insulin/GLP-1RA combination products were
studied in the DUAL program (NCTs 01336023,
01392573, 01676116, 01618162, 01952145, and
02298192) and the LixiLan program (NCTs
02058160 and 02058147). Compared with basal
insulin, insulin/GLP-1RA fixed-ratio combinations are superior at reducing HbA1c with weight
neutrality or weight loss rather than weight gain,
as well as reduced hypoglycemia rates, and
reduced insulin-dose requirement with IDegLira.
A combination of different medications may
often be required to achieve glycemic control,
and fixed-ratio combination products allow such
therapies to be given in simple regimens. Clinical
trial data for these products highlight the great
potential of these agents, not merely their efficacy and safety but also their ease of use and
decreased injection burden for patients.
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INTRODUCTION
Type 2 diabetes (T2D) is a progressive multiorgan disease [1–3] that accounts for approximately 90% of all cases of diabetes; hence, it is a
major cause of morbidity and mortality in both
high-income and developing countries [4, 5].
T2D is a substantial health-economic burden in
the Western world, with over 11% of total global
healthcare expenditure attributed to diabetes
(types 1 and 2) and one in five US healthcare
dollars spent on caring for a person with diabetes
[5, 6]. Effective therapies that can improve the
health of diabetes patients and reduce the
healthcare cost to society are therefore required.
One regimen that has increased in popularity in recent years, because of the complementary actions of its components, is the
combination of a basal insulin and glucagon-like
peptide-1 (GLP-1) receptor agonist (GLP-1RA).
Although this is an effective strategy, it requires
multiple injections, which has led to the development of fixed-ratio combination products that
require only one injection per day and so could
simplify treatment. Our review considers the
rationale for such products and the practicalities
of initiating and using them for optimal effect in
the clinical setting.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. Studies were identified by searching PubMed and abstracts accepted by the
American Diabetes Association (ADA), using the
names of the combination products and their
mono-components as search terms.

RATIONALE FOR BASAL
INSULIN ? GLP-1RA
COMBINATION THERAPIES
T2D Treatment Issues
The main features of T2D are declining b-cell
function, global insulin resistance, and loss of
the prandial insulin response with a corresponding lack of suppression of postprandial
glucagon release [2]. By the time of diagnosis,
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b-cell function may have decreased by 50%, and
patients with the greatest disease progression
before diagnosis may have lost over 80% of their
b-cell function [7–9]. The rate of progression of
b-cell failure defines the rate of progression of
T2D [8], so interventions must be intensified
accordingly in a timely manner; hence, patients
rarely remain on their initial therapy regimen.
Timely intensification of treatment helps
patients to maintain glycemic control, which is
easier than trying to gain or regain control. This
is important because a reduction in glycated
hemoglobin (HbA1c) is associated with a corresponding reduced risk of both microvascular
and macrovascular complications [2, 10]. Even
when therapy is intensified, glycemic control
can be lost over time because of the progressive
nature of the disease. Less than 30% of adults
with T2D reach and maintain HbA1c at less than
7.0% (less than 53 mmol/mol) within 3 years of
being started on basal insulin [11], and in one
study, 57.6% of those who achieved their HbA1c
goal did not sustain it [12].
In the past, when basal insulin alone was
insufficient to maintain glycemic control, the
only effective intensification option for
addressing postprandial glucose (PPG) control
was to add mealtime bolus insulin, or switch to
premixed insulin products. Control of PPG is
key because postprandial hyperglycemia contributes to HbA1c, especially at lower HbA1c
concentrations, and is widely considered to be
an independent risk factor for micro- and
macrovascular complications [10, 13]. ADA
guidelines state that PPG should be less than
180 mg/dL 1–2 h post-meal [13]. Clinicians
should be purposeful in titrating insulin dose to
achieve a target fasting glucose, but should also
know when to look at the contributions of PPG
to the HbA1c levels, with bolus insulin or
GLP-1RAs considered logical intensifications
[14]. There are useful clinical tools to help the
clinician in identifying such patients: one is the
Accurate Insulin Decisions website [15], which
provides guidelines covering when it is appropriate to consider intensifying a patient’s insulin therapy, such as a total daily basal dose at or
exceeding 0.5 units/kg of basal insulin. Second,
the BeAM value (differences between bedtime
and morning glucose), which identifies patients
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who need tighter PPG control rather than further increases in their basal insulin doses (when
the calculated difference is 45–55 mg/dL) [16].
There is a risk that patients who are not correctly identified as needing intensification
could continue to have inappropriate
‘‘over-basalization’’ rather than additional
therapies.
There are several known perceived barriers to
intensification of insulin therapy, including fear
of hypoglycemia [17], concerns about weight
gain [17], and patient difficulties with adherence,
such as when regimen and dosing calculation
complexity becomes challenging [17]. With the
number of therapeutic options increasing, the
wide range of potential combination regimens
can be daunting, and this perceived complexity
may actually contribute to delays in intensification. There is, therefore, an argument for the
development of easy-to-use, well-tolerated therapies combining basal insulin supplementation
with a component that can address PPG control
while minimizing these barriers.
Pharmacological Logic of Basal Insulin
plus GLP-1RA
The progressive nature of T2D means that,
eventually, many T2D patients will need exogenous insulin supplementation to maintain glycemic control [18, 19]. Exogenous basal insulin is
usually titrated to address control of fasting
plasma glucose (FPG) [19]. In addition, supplementing endogenous insulin may suppress
insulin release from the b-cell [20] to preserve
residual b-cell function [21], promoting a greater
endogenous prandial insulin response. Exogenous insulin can also help preserve b-cell function; although there are no data on human
patients, mouse models have shown that b-cells
can de-differentiate in response to hyperglycemia, with re-differentiation when euglycemia is achieved with exogenous insulin [22].
In healthy individuals, native GLP-1 is a
peptide hormone secreted by the gut wall in
response to nutrient ingestion, increasing
insulin secretion and inhibiting glucagon
secretion. GLP-1 also prolongs gastric emptying
[23], thereby lowering overall food intake [23],
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and this was thought to be the reason why
therapeutic agents based on GLP-1 resulted in
weight loss [23]. However, while this is true for
short-acting GLP-1RAs [24], recent findings
have demonstrated that for long-acting
GLP-1RAs, weight loss is mediated by regulation
of appetite signals in the brain [25]. A GLP-1RA
will therefore help optimize the prandial insulin
response to control PPG, reduce the insulin dose
requirement, and mitigate the weight gain
associated with insulin therapy. Unlike other
therapeutic options, its glucose-lowering action
is glucose dependent, thus GLP-1RA achieves
these benefits without the risk of hypoglycemia
associated with the use of rapid-acting prandial
insulins or sulfonylureas. Long-acting GLP-1RAs
can lower FPG in addition to simulating prandial insulin response, whereas short-acting
GLP-1RAs act primarily to inhibit gastric emptying, thus lowering PPG at the meal that follows dosing [24].
Owing to their different and complementary modes of action, the combination of basal
insulin and GLP-1RAs addresses seven of the
eight key defects seen in T2D [8, 9]. Insulin
decreases lipolysis in the adipocytes, while
GLP-1RAs augment insulin secretion, decrease
glucagon secretion from the pancreas, and thus
reduce hepatic glucose production. GLP-1RAs
also improve insulin sensitivity in muscles by
promoting weight loss, thus reducing the lipid
levels in muscles, and improving muscle sensitivity to insulin [9]. GLP-1RAs supplement
any deficient incretin response in the intestine
by binding to and activating GLP-1 receptors
throughout the body, and reduce appetite signals in the brain. The only defect that insulin/
GLP-1RA combination products do not address
is increased glucose reabsorption from the
kidney [8, 9].
Because of these theoretical benefits, many
studies have assessed and demonstrated the
clinical feasibility and value of treating patients
with GLP-1RAs plus basal insulin. These studies
have been subject to a recent systematic review
in which the majority of them demonstrated
improved glycemic control, without hypoglycemia or weight gain, when GLP-1RA was
added to basal insulin therapy [26]. With the
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clinical benefits of this approach well established, a logical progression has been the
development of fixed-ratio combination products that simplify the practical use of the regimen for patients. By combining a basal insulin
and GLP-1RA in a single injection pen, patients
can potentially benefit from a simplified regimen with reduced frequency of injections.

COMBINATION PRODUCTS
The first fixed-ratio basal insulin/GLP-1RA
combination products were approved by the US
Food and Drug Administration (FDA) in
November 2016 [27, 28]. These products were
XultophyÒ 100/3.6 (IDegLira) and SoliquaTM
100/33 (IGlarLixi) [27, 28]. XultophyÒ was also
approved by the European Medicines Agency
(EMA) in September 2014 [29], and SoliquaÒ
was approved by the EMA in January 2017 [30].
IDegLira—Novo Nordisk A/S, Bagsværd,
Denmark
IDegLira is a fixed-ratio combination of insulin
degludec (IDeg) and liraglutide, containing
100 units/mL (U/mL) of IDeg and 3.6 mg/mL of
liraglutide in a 3-mL prefilled injection pen [19].
IDeg is a long-acting basal insulin that
achieves its protracted action through multihexamer formation in the subcutaneous injection depot [31]. IDeg has a half-life of over 24 h
[32], meaning that with once-daily dosing, a
steady state is achieved with little pharmacodynamic variability [31]. This results in a predictably flat and stable glucose-lowering action
with a low risk of hypoglycemia compared with
insulin glargine 100 units/mL (IGlar U100)
[33, 34]. Recently, IDeg was shown to be superior to IGlar U100 in terms of rates of severe
hypoglycemia in the DEVOTE study, rate ratio
0.60 (95% CI 0.48, 0.76), p\0.001 for superiority [35]. The DEVOTE study also showed that
IDeg was non-inferior to IGlar U100 with regard
to incidence rates of major adjudicated cardiovascular events (MACE); hazard ratio 0.91 (95%
CI 0.78, 1.06), p\0.001 for non-inferiority [35].
Liraglutide is a once-daily analogue of
human GLP-1 with 97% amino acid sequence
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homology to endogenous GLP-1 [36]. Liraglutide reduces both FPG and PPG excursions [17]
via its glucose-dependent effects on b- and a-cell
function [17]. Protraction is achieved through
self-association as heptamers in the depot,
albumin binding in the circulation, and resistance to dipeptidyl peptidase-4 (DPP-4; an
enzyme that rapidly degrades endogenous
GLP-1), resulting in a half-life of approximately
13 h, which means that a 24-h action is
achieved with once-daily dosing. In the LEADER cardiovascular outcomes trial (CVOT),
liraglutide was shown to be superior to placebo
when analyzing the incidence rates of MACE;
hazard ratio 0.87 (95% CI 0.78, 0.97), p\0.001
for non-inferiority, p = 0.01 for superiority [37].
IGlarLixi—Sanofi-Aventis, Bridgewater,
NJ, USA
IGlarLixi is a fixed-ratio combination of insulin
glargine (IGlar) and lixisenatide, containing
100 U/mL of IGlar and 33 lg/mL of lixisenatide
in a 3-mL prefilled injection pen [28, 38, 39]. Two
co-formulations were developed: Pen A, with a
ratio of 2 U of IGlar and 1 lg of lixisenatide; and
Pen B, with a ratio of 3 U of IGlar and 1 lg of
lixisenatide [38]. Pen B was approved by the FDA
in November 2016 [28]. It is worth noting that
the Pen B used during the LixiLan trials had a
dose range 30–60 U, whereas the Pen B approved
by the FDA allows a starting dose of 15 U.
IGlar U100 is a basal insulin that achieves a
protracted action through post-injection precipitation, which retards absorption and results in an
action time of approximately 24 h, enabling
once-daily dosing in most patients [40–42].
Lixisenatide is a once-daily injectable, synthetic, exendin-derived GLP-1RA for which PPG
lowering is brought about mostly through delayed
gastric emptying and reduced glucagon release
[38, 39]. Lixisenatide is resistant to DPP-4, binds the
GLP-1 receptor with high affinity, but has a half-life
of only 2–4 h [43]. This relatively shorter half-life
means that in the clinical study program, lixisenatide has been dosed before patients’ main meals to
gain the maximum benefit. In the ELIXA CVOT,
lixisenatide was found to be non-inferior to placebo in terms of risk of MACE [44].
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These two combination products—IDegLira
and IGlarLixi—are both titrated in a similar
fashion to a basal insulin, although different
titration regimens were used in the clinical
development programs. Titration allows a gradual increase in the GLP-1RA dose, thereby
enabling the avoidance of nausea, the most
common side effect of GLP-1RAs [38]. Healthy
eating can also help minimize this side effect and
has the benefit of improving glucose further.

Evidence of Clinical Benefit
The clinical utility of these combination products has been established through a series of
phase 3 efficacy and safety trials. No new studies
of human or animal subjects have been performed by any of the authors for this article.
For IDegLira, these were the ‘‘DUAL’’ trials,
with DUAL I–VI studies published; key results are
summarized in Table 1. Direct comparisons of
results should not be made across these trials as
different patient populations were studied in
each. IDegLira was initiated with doses of 10 U
(10 U insulin degludec/0.36 mg liraglutide) for
DUAL I [19], DUAL IV [45], and DUAL VI [46],
and 16 U (16 U insulin degludec/0.58 mg
liraglutide) for DUAL II [17], DUAL III [47], and
DUAL V [48]. IDegLira improved glycemic control and mitigated the primary side effects of
insulin and GLP-1RA therapy in patients
uncontrolled on oral antidiabetic drugs (OADs;
DUAL I main trial and extension, DUAL IV, and
DUAL VI), basal insulin (DUAL II and DUAL V),
or GLP-1RA therapy (DUAL III) [17, 19, 45–48].
IDegLira resulted in significantly greater HbA1c
reductions versus either of its mono-components
(DUAL I main trial and extension) [19], and
superior HbA1c reductions were observed with
IDegLira versus IGlar U100 up-titration (DUAL V)
[48] and versus unchanged GLP-1RA therapy
(DUAL III) [47]. IDegLira was weight-neutral in
patients uncontrolled on OADs, resulted in
weight loss in those uncontrolled on basal insulin, and weight gain in those uncontrolled on
GLP-1RA. Rates of confirmed hypoglycemia
ranged between 1.5 and 3.5 events/patient-year
of exposure (PYE) in DUAL I–V, with the highest
rates being observed in DUAL III and DUAL IV, in
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which background therapy included sulfonylureas [17, 19, 45, 47, 48]. Nausea occurred in no
more than 4% of patients receiving IDegLira at
any given time in DUAL I–V [17, 19, 45, 47, 48].
IGlarLixi safety and efficacy analyses were
previously conducted in the LixiLan-O and LixiLan-L trials [38, 39]. Key results are summarized
in Table 2. These two 30-week studies demonstrated superior HbA1c reductions versus lixisenatide in patients uncontrolled on OADs
(LixiLan-O) and versus IGlar U100 in patients
uncontrolled on basal insulin (LixiLan-L)
[38, 39]. Non-inferior HbA1c reductions with
IGlarLixi versus IGlar U100 were also seen in
patients uncontrolled on OADs (LixiLan-O) [39].
Change in body weight from baseline to end of
trial was –0.3 kg and –0.7 kg in LixiLan-O and
LixiLan-L, respectively, and rates of documented
symptomatic hypoglycemia were 1.4 and
3.0 events/patient-year. In terms of gastrointestinal adverse events, nausea occurred in 9.6%
and 10.4% of patients in the LixiLan-O and LixiLan-L trials, respectively (Table 2) [38, 39].
It is worth noting that direct comparisons
between the results of the LixiLan and DUAL
studies should not be made because of the different study designs, patient populations,
interventions, and definitions used. At the time
of writing, no head-to-head studies have been
conducted. However, there have been previous
comparisons of the individual components. A
meta-analysis comparing hypoglycemia rates at
equivalent HbA1c values in IDeg and IGlar U100
found similar improvements in HbA1c values
with significantly fewer overall confirmed
hypoglycemic episodes in favor of IDeg [33].
Meanwhile, liraglutide has been shown to
reduce HbA1c to a statistically significantly
greater extent versus lixisenatide when added to
metformin in a 26-week, head-to-head study,
with an estimated treatment difference (ETD)
–0.62% (95% CI –0.8, –0.4), p\0.0001 [49]. A
greater proportion of patients reached either
HbA1c less than 7%/less than or equal to 6.5%
(less than 53/less than or equal to
48 mmol/mol) with liraglutide versus lixisenatide (74.2% vs. 45.5%/54.6% vs. 26.2%
respectively, p\0.0001 for both) [49]. While
liraglutide was associated with a greater reduction in mean 9-point self-measured plasma
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N/A

–2.7e
29 (8)
45e
135g
–58e
1.5h
0.2h

–0.5 (3.5)a
N/A
38 (13)*a
128 (32)*
–58a*
1.8c
0.2c

Mean Dweight from baseline,
kg (SD)

Baseline daily mean insulin dose,
U (SD)

Final daily mean insulin dose,
U (SD)

EOT mean 9-point SMPG,
mg/dL (SD)

D mean 9-point SMPG from
baseline, mg/dL (SD)

Conﬁrmed hypoglycemia rates,
events per PYE

Nocturnal hypoglycemia rates,
events per PYE

108 (28.8)*

0.5n

2.8n

N/A

N/A

?2.0 (3.9)i

–54 (41)i*

112
–62 (53)e

101 (32.4)*
–65a*

63f

75

f

-14.5

0.5j

3.5j

–40 (3.8)e*

N/A

28

N/A

?0.5e

–47 (47)e*

117*

64b

79

b

-16

6.4 (0.8)
–1.5 (0.8)

–1.3 (0.8)i

7.9 (0.6)

Insulin naı̈ve

SU ± met

DUAL IV
[45]
n 5 289/288

6.4 (0.8)

Mean DFPG from baseline,
mg/dL (SD)

45f

60

–1.9

7.8 (0.6)

Insulin naı̈ve

GLP-1RA** ?
Met ± pio ± SU

DUAL III [47]
n 5 292/291

Mean EOT FPG, mg/dL (SD)

70b

% patients achieving
HbA1c B 6.5%

b

81

f

-21*

Mean DHbA1c, mmol/mol

% patients achieving
HbA1c \ 7.0%

-21

–1.9 (1.1)

Mean DHbA1c, % (SD)

6.9

6.4 (1.0)

Mean EOT HbA1c, % (SD)

8.7 (0.7)

Basal insulin 20–40 U
daily ? Met ±
SU/glinides

DUAL II [17]
n 5 199/199

8.3 (0.9)

Insulin naı̈ve

Met ± pio

DUAL I [19]
n 5 833/825

IDegLira

Mean baseline HbA1c, % (SD)

Population

FAS/SAS

Table 1 Key efﬁcacy and safety results for IDegLira from DUAL trials I, II, IV, V, and VI [17, 19, 45–48]

m

0.2l

2.2l

–46 (44.9)k

137 (35)

41a

31 (10)

–1.4 (3.5)a

–50a*

110 (38.4)

55

72

m

-20*

–1.8 (1.1)

6.6 (0.9)

8.4 (0.9)

IGlar U100 20–50 U
daily ? Met

DUAL V [48]
n 5 278/278

N/A

N/A

N/A

N/A

41o

11

–1.0o

–78o

N/A

83.6p

90

p

-22

–2.0 (1.1)o

6.1

8.2 (0.9)

Insulin naı̈ve

Met ± pio

DUAL VI
[46] 1WT
n 5 210/209

N/A

N/A

N/A

N/A

41o

11

–2.0o

–82o

N/A

85.0p

90p

-22

–2.0 (1.0)o

6.0

8.1 (0.9)

Insulin naı̈ve

Met ± pio

DUAL VI
[46] 2WT
n 5 210/210
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DUAL II [17]
n 5 199/199
7

DUAL I [19]
n 5 833/825

9d

IDegLira

3

DUAL III [47]
n 5 292/291
5

DUAL IV
[45]
n 5 289/288
9

DUAL V [48]
n 5 278/278
5

DUAL VI
[46] 1WT
n 5 210/209
5

DUAL VI
[46] 2WT
n 5 210/210

Data aligned to number of decimal places across each individual row
ANCOVA analysis of covariance, BID twice daily, EOT end of trial, FAS full analysis set, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide
combination, IGlar U100 insulin glargine 100 units/mL, LOCF last observation carried forward, Met metformin, MMRM mixed model for repeated measurement, N/A not available, OAD oral antidiabetic
drug, OD once daily, PG plasma glucose, pio pioglitazone, PYE patient-year of exposure, SAS safety analysis set, SD standard deviation, SMPG self-measured plasma glucose, SU sulfonylurea, U units, 1WT
once-weekly titration, 2WT twice-weekly titration, % percentage of treatment arm
*If data not available in mg/dL, mmol/L data were converted using http://www.diabetes.co.uk/blood-sugar-converter.html; if HbA1c data only available in %, converted to mmol/mol using http://www.
diabetes.co.uk/hba1c-units-converter.html
** Liraglutide OD/exenatide BID
a
ANCOVA with treatment (stratiﬁcation factors for DUAL I) and country as ﬁxed factors, and baseline value as covariate. Analysis done on FAS using LOCF to impute missing values
b
Logistic regression model (with LOCF for missing values)
c
FAS using a negative binomial regression model with treatment, stratiﬁcation factors, and country as ﬁxed factors, and treatment-emergent time period (on or after the ﬁrst day of treatment and no later
than 7 days after the last day of treatment) as offset
d
Occurred on or after the ﬁrst day of exposure to treatment and no later than 7 days after the last day of treatment; reported by at least 5% of participants in any one treatment group, data are from the SAS
e
ANCOVA model with treatment, previous glucose-lowering drugs and country as ﬁxed factors, and baseline value as covariate (plus HbA1c for dose)
f
Logistic regression model with treatment, region, and previous glucose-lowering drugs as ﬁxed factors, and baseline value(s) as covariate(s)
g
Area under the proﬁle (calculated using the trapezoidal method) divided by the measurement time
h
Negative binomial regression model with a log-link function and the logarithm of the time period in which a hypoglycemic episode was considered treatment emergent as offset. The model included
treatment, previous antidiabetes treatment, and region as ﬁxed factors
i
ANCOVA on the FAS. Treatment, pretrial GLP-1RA and region (Australia, Europe, or North America) were included as ﬁxed effects, with baseline HbA1c as covariate
j
Negative binomial regression model with treatment, geographical region and pretrial medication as ﬁxed factors, and log of the duration of treatment-emergent time period (on/after the ﬁrst day of
treatment and no later than 7 days after the last day of treatment) as offset
k
Linear mixed model with an unstructured residual covariance matrix for measurements within patient and with treatment, time point, region and interaction between treatment and time point as ﬁxed
effects, and baseline 9-point SMPG proﬁle values as covariates
l
Negative binomial regression model with a log link function and log of the exposure time as offset, which included treatment and region as ﬁxed factors
m
Generalized linear model with binomial distribution and identity link, which included treatment as a ﬁxed factor
n
Negative binomial regression model based on the FAS population, with treatment, pretrial GLP-1RA, and region included as ﬁxed factors, and the logarithm of the time period in which an episode was
considered treatment emergent as offset
o
A standard MMRM with unstructured covariance matrix. The model included treatment, visit, region, and previous OAD treatment as ﬁxed factors, and the corresponding baseline value as a covariate
p
Logistic regression model based on FAS with treatment, region, and previous treatment as ﬁxed factors, and baseline HbA1c as covariate. Conﬁrmed hypoglycemia was deﬁned as episodes in which the PG
value was less than 56 mg/dL (regardless of symptoms) or if classiﬁed as severe (requiring assistance). Conﬁrmed hypoglycemic episodes with an onset between 00:01 and 05:59 (inclusive) were classiﬁed as
nocturnal

Nausea, % of participants

FAS/SAS

Table 1 continued
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Table 2 Key efﬁcacy and safety results for IGlarLixi from LixiLan-O [39] and LixiLan-L [38]
IGlarLixi

Population
Run-in phase
Baseline HbA1c, % (SD)

LixiLan-O [39]
n 5 468

LixiLan-L [38]
n 5 367

Met ± 2nd OAD
Insulin naı̈ve

Basal insulin 15–40 U
daily ± 1–2 OADs

4 weeks

6 weeks

Met

Met ? IGlar U100

8.1 (0.7)

8.1 (0.7)

a

EOT HbA1c, % (SD)

6.5 (0.8)

6.9 (0.9)a

Mean DHbA1c, % (SD)

–1.6 (0.04)

–1.1 (0.06)

Mean DHbA1c, mmol/mol

-17

-7

% patients achieving HbA1c \7.0%

74

b

55b

% patients achieving HbA1c B 6.5%

56b

34b

EOT FPG, mg/dL (SD)

113.4 (6.3)*

DFPG from baseline, mg/dL (SD)

b

–63.0 (1.8) *

Dweight from baseline, kg (SD)

–0.3 (0.2)

Baseline daily mean insulin dose, U (SD)

N/A

b

122 (41)
–6 (3)b
–0.7 (0.2)b
27 (8)

Final daily insulin dose, U (SD)

40 (15)

EOT mean 7-point SMPG, mg/dL (SD)

N/A

b

47 (13)b
140 (31)

b

D mean 7-point SMPG from baseline, mg/dL (SD)

–0.69 *

–27 (2)b

D 2-h postprandial glucose from baseline, mg/dL

–102.6 (3.6)d*

–85 (6)d

Conﬁrmed hypoglycemia rates, events per PYE

1.4c

3.03c

Nocturnal hypoglycemia rates, events per PYE

N/A

N/A

Nausea, % of participants

9.6

10.4

ANCOVA analysis of covariance, EOT end of trial, FAS full analysis set, FPG fasting plasma glucose, IGlar U100 insulin
glargine 100 units/mL, IGlarLixi insulin glargine/lixisenatide combination, Met metformin, N/A not available, OAD oral
antidiabetic drug, PG plasma glucose, PYE patient-year of exposure, SAS safety analysis set, SD standard deviation, SMPG
self-measured plasma glucose, U units, % percentage of treatment arm
* If data not available in mg/dL, mmol/L data were converted using http://www.diabetes.co.uk/blood-sugar-converter.html
a
Mixed-effect model with repeated measures with treatment groups, randomization strata of HbA1c (\8.0%, C8.0%),
randomization strata of second oral glucose-lowering therapy use at screening, visit, treatment-by-visit interaction, and
country as ﬁxed effects, and baseline outcome measure value by visit as a covariate
b
A mixed-effect model with repeated measures with treatment groups, randomization strata of HbA1c (\8.0%, C8.0%),
randomization strata of second oral glucose-lowering therapy use at screening, visit, treatment-by-visit interaction, and
country as ﬁxed effects and baseline outcome, and Cochran–Mantel–Haenszel method stratiﬁed by randomization strata
c
Number of events divided by total PYE. PYE calculated as time from the ﬁrst to the last injection of investigational drug
plus 1 day; documented symptomatic hypoglycemia = typical symptoms of hypoglycemia accompanied by a measured PG
concentration of less than 70 mg/dL (3.9 mmol/L) or 60 mg/dL (3.3 mmol/L)
d
ANCOVA model with treatment groups, randomization strata of HbA1c (\8.0%, C8.0%), randomization strata of
second oral glucose-lowering therapy use at screening, and country as ﬁxed effects, and baseline 2-h postprandial PG
excursion value as a covariate. N is number of patients, where FAS and SAS are not detailed
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glucose (SMPG; p\0.0001), lixisenatide was
associated with a smaller PPG excursion versus
liraglutide, but only for the first meal eaten after
the daily injection (p\0.05), with no statistical
difference between the two treatments across all
meals [49]. Body weight reductions and adverse
events, including hypoglycemic events, were
similar for both GLP-1RAs [49]. In an 8-week
trial in 2015, Meier et al. demonstrated comparable end-of-trial HbA1c values for lixisenatide 20 lg (6.2% ± 0.4) compared with
liraglutide 1.2 mg (6.1% ± 0.3) and liraglutide
1.8 mg (6.1% ± 0.3) [50]. Marginal mean treatment differences were not significant with
lixisenatide 20 lg versus liraglutide 1.2 mg
[–0.1% (95% CI –0.2, 0.03), p = 0.17]; however,
liraglutide 1.8 mg had a significant marginal
mean treatment difference versus lixisenatide
20 lg [–0.2% (95% CI –0.3, –0.05), p = 0.007]
[50]. Lixisenatide produced a greater reduction
in the incremental area under the curve (AUC)
between time points 00:30 and 04:30 (AUC
PPG00:30–04:30h) compared with liraglutide doses
of 1.2 and 1.8 mg (ETD –108.3 h mg/dL and
–83.0 h mg/dL, respectively; both p\0.001)
[50]. There was no statistically significant difference in FPG reductions between lixisenatide
and either dose of liraglutide [50]. In this study,
the most common adverse events reported were
nausea and symptomatic hypoglycemia. Lixisenatide 20 lg and liraglutide 1.2 mg had similar
proportions of patients reporting nausea, 18.8%
and 17.0% respectively, while 23.4% of patients
on liraglutide 1.8 mg reported nausea [50]. A
greater proportion of patients on lixisenatide
20 lg reported symptomatic hypoglycemia than
patients on liraglutide 1.2 mg or 1.8 mg (29.2%,
19.1%, and 21.3% of patients, respectively) [50].

PRACTICALITIES (WITH WHOM,
HOW, AND WHEN DO I USE
COMBINATION PRODUCTS?)
Target Population
Patients who would benefit from intensification
include those in whom HbA1c values remain
high despite an acceptable FPG (although this
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was only a requirement in the LixiLan trials, not
the DUAL trials), those with glucose variability
in the morning, and those whose total daily
basal insulin dose is greater than 0.5 units/
kg/day. HbA1c values do not give an accurate
picture of glycemic variability, and patients can
be at goal for FPG levels while still having HbA1c
above target. Previous treatment is also a factor
as those patients unable to achieve glycemic
control on GLP-1RA- or basal insulin-based
regimens, especially when PPG increments are
limiting HbA1c target achievement, could benefit from switching. In addition, there may be
patients who will benefit from the relative
simplicity of these products; a patient on a
basal–bolus insulin regimen could potentially
see their weekly number of total injections
decrease from 28 to 7 if switched to a fixedratio combination insulin/GLP-1RA product.
Another target population would be one
where further intensification of therapy is being
delayed because of fears surrounding potential
weight gain and hypoglycemic episodes. A regimen that does not increase the daily number of
basal insulin injections, while still promoting
weight loss and reduced frequencies of hypoglycemic episodes, could be more acceptable,
thus improving adherence. This is supported by
findings in DUAL V, where the patient-reported
outcomes (PROs) questionnaire (i.e., Treatment-Related Impact Measure For Diabetes, or
TRIM-D) showed an improvement in overall
score for IDegLira compared with IGlar U100,
mostly because of the large differences in scores
in diabetes management, ETD 7.2 (95% CI 4.2,
10.2), p\0.001, and treatment burden, ETD 3.7
(95% CI 0.7, 6.8), p = 0.017 [48]. These outcomes were not reported in the LixiLan-L and
LixiLan-O trials, although IGlarLixi is also
injected once a day, so one might assume that
similar benefits would be felt. The aforementioned benefits are likely to make IDegLira and
IGlarLixi, which target several physiological
defects of T2D, more attractive options to
patients, thereby tackling clinical inertia with
insulin intensification. This is important
because the earlier in the disease trajectory they
are introduced, the greater impact they will
have on slowing b-cell deterioration [51, 52].
However, it is worth noting that while both
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products are approved for use in the EU in
patients with inadequate glycemic control on
OADs [29, 30], in the USA both products are
only licensed for use in patients with inadequate glycemic control on basal insulin or their
respective GLP-1RA mono-components [27, 28].
It is important to acknowledge, however,
that while most recent official diabetes treatment guidelines address the mono-components
of IDegLira and IGlarLixi, they do not yet
specifically cover fixed-ratio combination
products [53]. The overall cost of the fixed-ratio
combination products should also be taken into
account when making the decision to commence a patient on a new or intensified therapy. These medications are expensive;
therefore, the insurance status of US patients
should be taken into account.

Table 3 Titration algorithm for combination products

Above target
range

?2 U (2 U IGlar U100 and
0.66 lg lixisenatide) to ?4 U
(4 U IGlar U100 and 1.32 lg
lixisenatide)

How to Use

Within target
range

No adjustment

IDegLira is given by once-daily subcutaneous
injection, with the injection ideally being
administered consistently at the same time of
day (which can vary from patient to patient),
with or without food [19, 27]. Injection sites
should be rotated between the thigh, upper
arm, and abdomen [27]. The pens are prefilled
for single-patient use only. The product is contraindicated in the following patients: those
with a personal or family history of medullary
thyroid carcinoma, because of its liraglutide
component; those with multiple endocrine
neoplasia syndrome type 2; those experiencing
hypoglycemia episodes; or those with hypersensitivities to IDegLira, IDeg, or liraglutide
[27].
The recommended initial dosing of IDegLira
is 16 U, which delivers 16 U IDeg and 0.58 mg
liraglutide [27]. The maximum dose is 50 U,
which delivers 50 U IDeg ? 1.8 mg liraglutide
[19, 27], the maximum approved dose of
liraglutide for T2D. The dose should be titrated
according to the mean of three or four consecutive prebreakfast SMPG results using the algorithm shown in Table 3, and according to the
individual patient’s glycemic target range. It is
important to note that maximum dose is not
required for efficacy.

Below target
range

–2 U (2 U IGlar U100 and 0.66 lg
lixisenatide) to –4 U (4 U IGlar U100
and 1.32 lg lixisenatide)

Mean fasting
SMPG

Dosage adjustment

IDegLira
Above target
range

?2 U (2 U IDeg and 0.072 mg
liraglutide)

Within target
range

No adjustment

Below target
range

–2 U (2 U IDeg and 0.072 mg
liraglutide)

IGlarLixi

IDeg insulin degludec, IDegLira insulin degludec/liraglutide combination, IGlarLixi insulin glargine/lixisenatide
combination, IGlar U100 insulin glargine 100 units/mL,
SMPG self-measured plasma glucose, U units
The most common side effects occurring in
more than 5% of patients treated with IDegLira
include nasopharyngitis, headache, nausea,
diarrhea, raised lipase, and upper respiratory
tract infections [27]. If patients consistently
require doses under 16 U or over 50 U of IDegLira,
then switching to alternative therapies should be
considered. There are very few significant drug
interactions, details of which can be found in the
Highlights of Prescribing Information [27].
IGlarLixi is given by once-daily subcutaneous injection [38, 39], with the injection
being administered within 1 h of the first meal
of the day [28]. The pen is prefilled for singlepatient use only. Injection sites should be
rotated between the thigh, upper arm, and
abdomen [28]. IGlarLixi is contraindicated in
patients experiencing hypoglycemia episodes,
or those with hypersensitivities to IGlarLixi,
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IGlar U100, or lixisenatide [28]. There are no
thyroid-related contraindications with products
containing lixisenatide, unlike liraglutide.
Antibiotics, certain analgesics, or other medications that are particularly dependent on
threshold concentrations for efficacy, or for
which a delay in effect is undesirable, should be
administered at least 1 h before or 11 h after
IGlarLixi injection.
Other basal insulin or GLP-1RA therapies
should be discontinued before initiating
IGlarLixi. The recommended initial dosing of
IGlarLixi for patients previously uncontrolled
on lixisenatide or on less than 30 U basal
insulin is 15 U, which delivers 15 U IGlar and
5 lg lixisenatide, and for patients previously
uncontrolled with 30–60 U of basal insulin, the
recommended starting dose of IGlarLixi is
30 U, which delivers 30 U IGlar and 10 lg
lixisenatide [28]. The maximum dose is 60 U
IGlar ? 20 lg lixisenatide [28]. The dose should
be titrated once a week using the algorithm
shown in Table 3, according to the individual
patient’s glycemic target range.
IGlarLixi should be administered up to 1 h
before the first meal daily, although the maximum dose is not required for efficacy. The most
common
side
effects
include
nausea,
nasopharyngitis, diarrhea, upper respiratory
tract infection, and headache [28]. If patients
consistently require doses of IGlarLixi under
15 U or over 60 U, switching to alternative
therapies should be considered.
There are few significant drug interactions,
details of which can be found in the Highlights
of Prescribing Information [28].
Storage Information
Both IDegLira and IGlarLixi should be stored in
a refrigerator at 36–46 °F (2–8 °C) before use,
and should not be frozen. After the first injection, IDegLira can be stored either at room
temperature (59–86 °F; 15–30 °C) or in the same
refrigerator as before first use for 21 days, away
from direct heat or light. Each pen should be
used for a maximum of 21 days [27]. After the
first injection, IGlarLixi should be stored at
room temperature (below 86 °F; 30 °C) for
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14 days, away from direct light. The pen should
be discarded 14 days after the first use [28].
Advice for Demonstrating Injection
Technique
Many patients are intimidated by the prospect
of initiating or changing injection therapy, so
they often welcome a practical demonstration
by their diabetes healthcare provider. Given the
titration methods used for IDegLira and IGlarLixi, a demonstration will be especially beneficial if the patient has not used a basal insulin
before. Educational videos demonstrating
injection techniques can be found online. A
checklist of items to explain or show to the
patient may also be helpful, and can be found in
the Supplementary Material.

CONCLUSIONS
Type 2 diabetes is a progressive, multi-system
disease that affects a large proportion of the
global population. Because of its complex
pathophysiology, a combination of different
medications may often be required to achieve
glycemic control, and fixed-ratio combination
products allow such therapies to be given in
simple regimens.
Basal
insulin/GLP-1RA
fixed-ratio combination products can help in
this respect by addressing seven of the eight key
defects found in advanced T2D [7, 8]. Compared with basal insulin, insulin/GLP-1RA
fixed-ratio combinations are superior at reducing HbA1c [17, 38, 47], with the added advantage of weight neutrality or weight loss rather
than weight gain, as well as reduced hypoglycemia rates, and reduced insulin-dose
requirement with IDegLira. These fixed-ratio
products are a relatively new addition to our
armamentarium and their clinical scope is still
under investigation. However, the combination
of basal insulin and GLP-1RAs is well studied
[54] and makes pharmacological sense. Clinical
trial data of these products highlight the great
potential of these agents, not merely of their
efficacy and safety but also their ease of use and
decreased injection burden for patients.
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